• Join
  • Login
  • Contact

Search abstracts

Buccal mucosal delivery of a peptide for the treatment of autoimmune diseases

  • In: SUBMITTED ORALS on Tuesday, 15 April 2014, 16:00-17:30
  • At: PSWC, Melbourne (Australia) (2014)
  • Type: Presentation
  • By: JIN, Liang (Monash University, Pharmaceutics, Melbourne, Australia)
  • Co-author(s): White, Paul (Monash University, Melbourne, Australia)
    Boyd, Ben (Monash University, Melbourne, Australia)
    Pennington, Mike (Peptides International, Louisville, United States of America)
    Norton, Raymond (Monash University, Melbourne, Australia)
    Nicolazzo, Joseph (Monash University, Melbourne, Australia)
  • Abstract:

    Background information: As a potent blocker of the voltage-gated potassium channel Kv1.3, ShK peptide can be potentially used as an immunomodulator for the treatment of autoimmune diseases. Indeed, ShK is currently undergoing Phase I clinical trials. However, systemic delivery of ShK is challenging as oral administration leads to poor..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses